Fig 1: Circulating FLRG and GASP-1 concentrations by LC-MS/MS in younger and older women and men. Box plots (25–75 percentile) and whiskers (Tukey method) showing comparisons of a FLRG, b GASP-1, c FLRG relative to myostatin, and d GASP-1 relative to myostatin between younger women (YW), older women (OW) and sarcopenic older women (SOW). Comparisons of myostatin inhibitors and their ratios to myostatin between corresponding groups of men are also illustrated (e-h). *, **, and *** denote p < 0.05, 0.01, and 0.001, respectively, compared to the younger group except when denoted with a bracket
Fig 2: Circulating FLRG and GASP-1 concentrations in women compared to men. Box plots (25–75 percentile) and whiskers (Tukey method) showing comparisons of a FLRG, b GASP-1, c FLRG relative to myostatin, and d GASP-1 relative to myostatin between younger women (YW) and younger men (YM) (top panel), older women (OW) and older men (OM) (middle panel), and sarcopenic OW (SOW) and sarcopenic OM (SOM) (bottom panel). *** denotes p < 0.001
Fig 3: Calibration curves for LC-MS/MS measures of myostatin, propeptide, GASP-1, and FLRG. Linear calibration curves for recombinant intact myostatin (a), propeptide (b), GASP-1 (c), and FLRG (d) diluted into bovine serum albumin over a concentration range of 0.031 to 1.00 nM
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human FLRG Protein